Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical)

v3.24.2.u1
CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical)
$ in Thousands
Jun. 30, 2024
USD ($)
Firm
Dec. 31, 2023
USD ($)
Firm
Investment Holding [Line Items]    
Investment, basis spread, variable rate 8.50% 8.50%
Aggregate Gross Unrealized Appreciation $ 119,000 $ 118,300
Aggregate Gross Unrealized Depreciation 158,600 115,900
Net Unrealized Appreciation (Depreciation) over cost for U.S. federal income tax purposes (39,600) 2,400
Aggregate cost of securities for U.S. federal income tax purposes (in billions) 3,600,000 3,200,000
Investment cost 3,609,118 3,247,033
Investments, at fair value: $ 3,568,539 $ 3,248,046
1-month SOFR    
Investment Holding [Line Items]    
Interest rate 5.34% 5.34%
3-month SOFR    
Investment Holding [Line Items]    
Interest rate 5.32% 5.36%
6-month SOFR    
Investment Holding [Line Items]    
Interest rate 5.25% 5.35%
Common Stock | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Investment Holding [Line Items]    
Number of publicly traded companies | Firm 33 36
Warrants | Significant Other Observable Inputs (Level 2)    
Investment Holding [Line Items]    
Number of publicly traded companies | Firm 23 24
Black Crow AI, Inc. affiliates | Promissory Note    
Investment Holding [Line Items]    
Principal amount $ 2,400 $ 2,400
Phathom Pharmaceuticals, Inc. | Royalty Contract    
Investment Holding [Line Items]    
Investment cost 12,000 12,000
Investments, at fair value: $ 10,500 $ 9,400